Cross-Talk Between Interferon-Gamma and IL-2 Signaling Regulates Antigen-Specific CD8 &lt;sup&gt;+&lt;/sup&gt; T-Cell Number

Jhala, Gaurang; Krishnamurthy, Balachander; Brodnicki, Thomas C.; Ge, Tingting; Akazawa, Satoru; Selck, Claudia; Trivedi, Prerak; Pappas, Evan G; Mackin, Leanne; Principe, Nicola; Brémaud, Erwan; George, David de; Boon, Louis; Smyth, Ian; Chee, Jonathan; Kay, Thomas; Thomas, Helen E.

doi:10.2139/ssrn.3919948

Cited by 1 publication

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Th1 cells (CD4+) are also necessary for combating intracellular pathogens such as M. tb . Th1 cells secrete cytokines such as interferon gamma (IFN‐γ) and Tumor necrosis factor‐α (TNF‐α) to invoke and interleukin‐2 (IL‐2) to activate T cells, as well as innate immune cells 15,16 . Bacillus Calmette Guérin (BCG) vaccine was first developed from the attenuated live strain of M. Bovis by Albert Calmette and Camille Guerin, two French scientists.…”

Section: Introductionmentioning

confidence: 99%

“…Th1 cells secrete cytokines such as interferon gamma (IFN-γ) and Tumor necrosis factor-α (TNF-α) to invoke and interleukin-2 (IL-2) to activate T cells, as well as innate immune cells. 15,16 Bacillus Calmette Guérin (BCG) vaccine was first developed from the attenuated live strain of M. Bovis by Albert Calmette and Camille Guerin, two French scientists. This vaccine is known as one of the most significant strategies to control the disease for a long time.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Liposomal delivery system/adjuvant for tuberculosis vaccine

Moradi

Vahedi

Abbassioun

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

As reported by the World Health Organization, about 10 million individuals were infected with tuberculosis (TB) worldwide. Moreover, approximately 1.5 million people died of TB, of which 214,000 were infected with HIV simultaneously. Due to the high infection rate, the need for effective TB vaccination is highly felt. Until now, various methodologies have been proposed for the development of a protein subunit vaccine for TB. These vaccines have shown higher protection than other vaccines, particularly the Bacillus culture vaccine. The delivery system and safety regulator are common characteristics of effective adjuvants in TB vaccines and the clinical trial stage.The present study investigates the current state of TB adjuvant research focusing on the liposomal adjuvant system. Based on our findings, the liposomal system is a safe and efficient adjuvant from nanosize to microsize for vaccinations against TB, other intracellular infections, and malignancies. Clinical studies can provide valuable feedback for developing novel TB adjuvants, which ultimately enhance the impact of adjuvants on next-generation TB vaccines.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%